Anju Completes Merger with OmniComm Systems to Form eClinical Entity

September 18, 2019

The merger creates a combined organization with a leading position in the eClinical market.

OmniComm Systems, a healthcare technology company, announced on Sept. 18, 2019 that Anju Software, a privately owned Abry Partners portfolio company and provider of comprehensive software solutions to life sciences companies, contract research organizations, and medical device manufacturers, has completed the acquisition of OmniComm Systems. Under the agreement, OmniComm is now a wholly owned subsidiary of Anju.

The merger creates a combined organization with a leading position in the eClinical solutions market, with particular expertise in electronic data capture and eSource. Anju is able to immediately add clinical trial management system (CTMS) and electronic trial master file (eTMF) capabilities, data migration and integration tools, and dynamic reporting that is integrated with existing solutions to the OmniComm suite of eClinical solutions. As part of the merger, OmniComm’s solutions, including its flagship TrialMaster and TrialOne products, will continue to be developed and supported with enhanced features to provide a complete eClinical suite.

“I have been working on this transaction with Anju for the past two years, and this merger represents the next chapter in OmniComm’s evolution from a small independent eClinical company into a more comprehensive global provider of software and services for the larger life sciences and medical device community,” said Randall Smith, founder and vice-chairman of OmniComm, in a company press release.

“By joining forces with Anju, we will accelerate our shared goal of becoming the best-in-class platform for eClinical solutions and clinical trials management,” added Stephen Johnson, president and CEO of OmniComm, in the press release.

“I am glad that two years of discussions with OmniComm has culminated in the acquisition of OmniComm by Anju. With the financial backing of Abry Partners and the new technology available at Anju, we can realize the potential that both companies have to become the leader in providing software, data, and services to the life sciences community,” said Kurien Jacob, founder and chairman of Anju Software, in the release. 

“This merger positions Anju as the fastest-growing provider in the eClinical arena, and the complementary products of the two companies now form a truly comprehensive eClinical suite,” commented Marc Eigner, CEO of Anju, in the release.

With the completion of the transaction on Sept. 18, 2019, shares of OmniComm’s common stock have been retired and shareholders have the right to receive $0.41032 per share, without interest, representing a 58% premium to the closing price on July 15, 2019, the day on which the merger was announced.

Source: OmniComm Systems